Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma

Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma

Abstract Background Belinostat is a histone deacetylase inhibitor approved for relapsed refractory peripheral T-cell lymphoma (PTCL). The primary objective of this study was to determine the maximum tolerated dose (MTD) of belinostat combined with CHOP (Bel-CHOP). Secondary objectives included safet...

Full description

Bibliographic Details
Main Authors: Patrick B. Johnston, Amanda F. Cashen, Petros G. Nikolinakos, Anne W. Beaven, Stefan Klaus Barta, Gajanan Bhat, Steven J. Hasal, Sven De Vos, Yasuhiro Oki, Changchun Deng, Francine M. Foss
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Experimental Hematology & Oncology
Subjects:
Peripheral T-cell lymphoma (PTCL)
Histone deacetylase inhibitor (HDACi)
Belinostat
CHOP
Online Access:https://doi.org/10.1186/s40164-021-00203-8

Internet

https://doi.org/10.1186/s40164-021-00203-8

Similar Items